Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Drugmakers Pfizer and Flynn Pharma have been ... so they were no longer subject to price regulations. Pfizer hiked the price of the drug between 780% and 1,600%, and also supplied the drug to ...

We estimate Pfizer’s valuation to be $32 per share, reflecting a solid nearly 40% upside. At its current price of $23, Pfizer stock trades at just 8 times trailing earnings of $2.91 per share.

The agreement covers the development, manufacturing and commercialisation of the drug. Pfizer has been granted a global license, excluding China, as well as the option to obtain commercialisation ...

CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public ...

Pfizer is facing another setback with its weight-loss pill, danuglipron. The pharmaceutical giant stopped development of the drug after liver issues affected one patient. The State of Kansas has ...

Additional milestone payments could reach up to $4.8 billion, alongside tiered double-digit royalties on future sales if the drug receives approval ... planning details or potential impacts on ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it ...